Ocriplasmin Research to Better Inform Treatment (ORBIT)
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Retinal disorders
- Focus Therapeutic Use
- Acronyms ORBIT
- Sponsors Oxurion; ThromboGenics
- 11 May 2017 According to a ThromboGenics media release, data from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2017 annual meeting
- 20 Jun 2016 Status changed from active, no longer recruiting to completed.
- 29 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.